Targeting TIGIT with tiragolumab does not improve outcomes over atezolizumab plus bevacizumab in untreated advanced hepatocellular carcinoma, shows a trial that questions the future of the approach.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tiragolumab-disappoints-untreated-advanced-hcc-2025a1000svv?src=rss
Author :
Publish date : 2025-10-23 13:44:00
Copyright for syndicated content belongs to the linked Source.